Dr. Leung is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
PO Box 13
Ringoes, NJ 08551- Is this information wrong?
Education & Training
- Massachusetts General HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 1993 - 1996
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1990 - 1993
- University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1989
- Washington UniversityA.B., Chemistry, Cum Laude
- University of IowaPh.D., Physiology and Biophysics
Certifications & Licensure
- NJ State Medical License 1998 - 2025
- MA State Medical License 1992 - 2015
Awards, Honors, & Recognition
- Iowa Graduate Fellow University of Iowa, 1986
- Phi Beta Kappa 1983
- Chancellor's Honorary Fellowship 1980
- Join now to see all
Publications & Presentations
PubMed
- Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study.Rizzoli R, Benhamou C, Halse J, Miller PD, Reid IR, Rodríguez Portales JA, DaSilva C, Kroon R, Verbruggen N, Leung AT, Gurner D> ;Osteoporos Int. 2016-06-01
- A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.Cosman F, Gilchrist N, McClung M, Foldes J, de Villiers T, Santora A, Leung A, Samanta S, Heyden N, McGinnis JP, Rosenberg E, Denker AE> ;Osteoporos Int. 2016-01-01
- Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacat...Bone, H. G.,Dempster, D. W.,Eisman, J. A.,Greenspan, S. L.,McClung, M. R.,Nakamura, T.,Papapoulos, S.,Shih, W. J.,Rybak-Feiglin, A.,Santora, A. C.,Verbruggen, N.,Leung...> ;Osteoporos Int. 2015 Sep 12
- Join now to see all
Journal Articles
- A Phase IIb, randomized, placebo-controlled, dose-ranging study of MK-5442 in the treatment of postmenopausal women with osteoporosisHalse J, Greenspan S, Cosman F, Ellis G, Scott B, Heyden N, Doleckyj S, Samanta S, He W, Santora A, Leung A, Denker A, J Clin Endo Metab, 8/1/2014
- Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 studyLangdahl B, Binkley N, Bone H, Gilchrist N, Resch H, Rodriguez Portales J, Denker A, Lombardi A, Le Bailly De Tilleghem C, DaSilva C, Rosenberg E, Leung A, J Bone Miner Res, 11/1/2012
- Randomized, active-controlled study of once-weekly alendronate 280-mg high-dose oral buffered solution for treatment of Paget's diseaseHooper M, Faustino A, Reid IR, Hosking D, Gilchrist NL, Selby P, Wu M, Salzmann G, West J, Leung A, Osteoporos Int, 1/1/2009
- Join now to see all
Abstracts/Posters
- Odanacatib Anti-Fracture Efficacy And Safety In Postmenopausal Women With Osteoporosis. Results from the Phase III Long-Term Odanacatib Fracture Trial (LOFT).McClung M, Langdahl B, Papapoulos S, Saag K, Adami S, Bone H, de Villiers T, Kiel D, Kung A, Kumar P, Lim S-K, Ling X, Lippuner K, Mautalen C, Nakamura T, Reginster J-..., J Bone Miner Res, 1/1/2014
- Safety and Tolerability of Odanacatib Therapy in Postmenopausal Women with Osteoporosis. Results from the Phase III Long-Term Odanacatib Fracture Trial (LOFT).Papapoulos S, McClung M, Langdahl B, Saag K, Adami S, Bone H, de Villiers T, Kiel D, Kung A, Kumar P, Lim S-K, Ling X, Lippuner K, Mautalen C, Nakamura T, Reginster J-..., J Bone Miner Res, 1/1/2014
- Eight Years of Continued Odanacatib Therapy for Postmenopausal Women with Low Bone Mineral Density: Results from an Open-Label Extension to a Phase IIB Study.Rizzoli R, Rodriguez Portales JA, Benhamou CL, Halse J, Miller PD, Reid I, Dasilva C, Kroon R, Leung A, Gurner D, Osteoporos Int, 1/1/2014
- Join now to see all
Other
- Thesis: The structural and functional characterization of the 1,4-dihydropyridine receptor of the voltage-dependent Ca2+ channel from rabbit skeletal muscle.Leung A, University of Iowa, Iowa City, IA
1/1/1988 - Liquid Bisphosphonate Formulations for Bone DisordersDaifotis A, Denker A., Bergquist P., and Leung A, U.S. Application No. 10/305868, Case 20921Y
- Dihydropyridine Receptor and Antibodies TheretoCampbell KP, Imagawa T, and Leung AT, United States Patent Number 4,912,202
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: